

ORIGINAL PAPER

Jürgen Brunner · Wagner F. Gattaz

Intracerebral injection of phospholipase A₂ inhibits dopamine-mediated behavior in rats: possible implications for schizophrenia

Received: 16 March 1995 / Accepted: 19 July 1995

Abstract Phospholipase A₂ (PLA₂) is a key enzyme in the phospholipid metabolism. In the CNS intracellular PLA₂ plays an essential role in signal transduction by affecting both dopamine (DA) release and DA-receptor sensitivity. In schizophrenia a disordered phospholipid metabolism and increased activity of PLA₂ have been reported. In this study we investigated the effects of intracerebral PLA₂ injections on dopaminergic neurotransmission in rats using Ungerstedt's model of rotational behavior. Circling behavior induced by the DA agonist apomorphine after unilateral PLA₂ injections into the substantia nigra pars compacta was recorded. Seven and 21 days after intranigral PLA₂ injection, apomorphine induced an ipsilateral rotation indicating a long-lasting inhibition of ipsilateral nigrostriatal dopaminergic pathway by PLA₂ application. In schizophrenia a reduced dopaminergic activity in the frontal cortex has been hypothesized. Recent spectroscopy studies reported on an accelerated breakdown of membrane phospholipids in the frontal cortex from schizophrenics. The present findings suggest that increased PLA₂ activity in schizophrenia could accelerate the breakdown of membrane phospholipids and thus contribute to a hypodopaminergy in the frontal cortex of schizophrenic patients.

Key words Phospholipase A₂ · Schizophrenia · Phospholipids · Rotational behavior · Hypofrontality

Introduction

The intracellular enzyme phospholipase A₂ (PLA₂) catalyzes the hydrolysis of membrane phospholipids to release free fatty acids and cytotoxic products such as lysophosphatidylcholine. In neuronal membranes phospholipase A₂ plays an essential role in signal transduction by

influencing the physicochemical properties of synaptic membranes (Farooqui et al. 1992).

In schizophrenic patients PLA₂ activity has been reported to be increased in plasma (Gattaz et al. 1987), serum (Gattaz et al. 1990; Noponen et al. 1993), and platelet membranes (Gattaz et al. 1995). In platelets of schizophrenics phosphatidylcholine concentration (substrate of PLA₂) was found to be decreased (Rotrosen and Wolkin 1987) and lysophosphatidylcholine concentration (breakdown product of PLA₂ hydrolysis) elevated (Pangerl et al. 1991). Taken together, these data suggest an accelerated breakdown of membrane phospholipids in schizophrenia.

A disordered phospholipid metabolism has also been reported in the brain of schizophrenics by means of *in vivo* ³¹P-NMR spectroscopy studies. Phosphomonoesters (PME) are the precursors and phosphodiester (PDE) are the breakdown products of membrane phospholipids in the brain. Phosphomonoesters were found to be decreased, and PDE to be elevated, in the frontal lobe of schizophrenic patients (Williamson et al. 1991; Deicken et al. 1993; Pettegrew et al. 1993) suggesting that an accelerated phospholipid breakdown may be found in some schizophrenic brains.

Because increased PLA₂ activity accelerates the phospholipid metabolism, we investigated in rats the effects of intracerebral injections of the enzyme on dopamine (DA)-mediated behavior. *In vitro* studies showed that increased PLA₂ activity influenced DA-receptor sensitivity (Anand-Srivastava and Johnson 1981; Oliveira et al. 1984) and DA synthesis and release (Bradford et al. 1983; Ohmichi et al. 1989). To our knowledge, there is only one *in vivo* investigation of the effects of intracerebral PLA₂ injections on DA-mediated behavior (Cadet et al. 1989). These authors reported apomorphine-induced ipsilateral circling behavior in rats pretreated with intranigral injections of PLA₂. However, these results need further experimental confirmation, because no control group was investigated by Cadet and collaborators. Additionally to the experiments of Cadet et al. (1989) we investigated in the present study the effects of PLA₂ at different doses, and we introduced placebo groups to control for the non-specific ef-

fects of intranigral saline injections on behavior in rats. Cadet et al. (1989) started rotometer testing 10 days after intranigral injection of PLA₂. In our experiments testing started on the first postoperative day to assess possible acute effects. We adopted the rotational model presented by Ungerstedt and Arbuthnott (1970) because it is an easily quantifiable and well-validated approach to monitoring dopaminergic activity in vivo.

Methods

Stereotaxic surgery

Adult female Sprague Dawley rats (Charles River/Wiga, Sulzfeld) weighing 223 ± 10 g (mean \pm SD) were anesthetized with 10 mg ketamine (Ketavet) s.c. per animal and 30 mg/kg pentobarbital (Nembutal) i.p. and mounted in a David Kopf stereotaxic frame with the incisor bar 5 mm above horizontal zero. The substances were injected unilaterally into the substantia nigra pars compacta (SNC) in a volume of 4 μ l at a constant rate of 1 μ l/min using a Hamilton microliter syringe (22 gauge). After completion of the injections, cannulas were left in place for an additional 3 min. The stereotaxic coordinates of the SNC (AP: 2.2 mm, L: 1.6 mm, DV: 2.5 mm from interaural line) were taken from the atlas of De Groot (1959). To validate stereotaxic precision nine rats received a unilateral intranigral injection of 8 μ g 6-hydroxydopamine (6-OHDA, Sigma) in 4 μ l of saline with 0.2 μ g/ μ l ascorbic acid added. These animals were pretreated with 10 mg/kg desipramine (Thomae) p.o. 60 min prior to surgery to protect noradrenergic nigral neurons. With these stereotaxic coordinates the results of Ungerstedt and Arbuthnott (1970) could be replicated. Methamphetamine (5 mg/kg s.c.) induced an ipsilateral asymmetry ($P < 0.01$) with (mean \pm SEM) 871 ± 69 ipsilateral and 4 ± 1 contralateral turns/h.

Experiment 1

PLA₂ isolated and purified from bovine pancreas (Sigma) with an enzymatic activity of 6.8 U/mg was unilaterally injected into the SNC in three different doses: 1 μ g PLA₂ ($n = 6$), 3 μ g PLA₂ ($n = 6$), and 5 μ g PLA₂ ($n = 6$). 1 U hydrolyzes 1 μ mol L- α -phosphatidylcholine to L- α -lysophosphatidylcholine and a free fatty acid per min at pH 8.0 and 37°C. The control group ($n = 6$) received unilateral intranigral vehicle injections (4 μ l of saline). Spontaneous rotational behavior was recorded for 30 min on days 1, 3, and 7 postoperatively. Seven days after stereotaxic surgery rotational behavior induced by 0.5 mg/kg apomorphine (APO) s.c. was recorded for 60 min.

Experiment 2

PLA₂ from bovine pancreas (Sigma) with a higher enzymatic activity (12 U/mg) was unilaterally injected into the SNC in two different doses: 20 μ g PLA₂ ($n = 11$) and 100 μ g PLA₂ ($n = 12$) dissolved in 4 μ l of saline. The control group ($n = 11$) received a unilateral intranigral injection of the vehicle (4 μ l of saline). Fourteen days after surgery spontaneous rotational behavior was recorded for 30 min. On day 21 postoperatively rotational behavior was monitored for 60 min after stimulation with 0.5 mg/kg APO (Sigma) s.c.

Rotational assessments

Rotational behavior was recorded automatically with a rotometer. Only complete turns (360°) in each direction were counted.

Statistics

Data were analyzed by nonparametric tests. The Mann-Whitney rank sum test was used for comparisons between different treatment groups. Rotational asymmetries (number of ipsilateral vs contralateral turns) within the same group were analyzed using Wilcoxon matched pairs signed rank test.

Results

Experiment 1

On the first postoperative day a spontaneous contralateral asymmetry was observed in all groups with low-dose intranigral PLA₂ application as well as saline-treated animals (range contralateral 34–43; ipsilateral 1–2 turns/30 min; $P < 0.001$ for all groups). The PLA₂ groups did not differ quantitatively from the saline group. The contralateral spontaneous asymmetry diminished in all treatment groups within the first postoperative week. Seven days after surgery 0.5 mg/kg APO induced an ipsilateral asymmetry only in PLA₂-treated rats. No APO-induced asymmetry was observed in saline-treated animals. Because no significant differences were found among the three PLA₂-dose groups (1 μ g ipsilateral 47 ± 20 , contralateral 5 ± 3 ; 3 μ g ipsilateral 30 ± 17 , contralateral 7 ± 2 ; 5 μ g ipsilateral 48 ± 24 , contralateral 22 ± 8 ; means \pm SEM), data were pooled as presented in Fig. 1.

Experiment 2

There was no spontaneous rotational asymmetry 14 days after unilateral intranigral injection of 20 μ g and 100 μ g PLA₂. The administration of 0.5 mg/kg APO 21 days postoperatively caused a significant ipsilateral asymmetry in




Fig. 1 Rotational behavior induced by 0.5 mg/kg apomorphine 7 days after intranigral injection of PLA₂ (pooled data 1, 3, and 5 μ g) and placebo (NaCl) (means \pm SEM). $P < 0.05$ compared with ipsilateral rotations




Fig. 2 Rotational behavior induced by 0.5 mg/kg apomorphine 21 days after intranigral injection of PLA₂ (pooled data 20 and 100 µg) and placebo (NaCl) (means ± SEM). $P < 0.001$ compared with ipsilateral rotations

PLA₂ pretreated rats, but not in the saline group (Fig. 2). The APO-induced ipsilateral rotation counts in this experiment did not differ between animals pretreated with 20 µg (ipsilateral 92 ± 15 , contralateral 15 ± 5) and with 100 µg PLA₂ (ipsilateral 96 ± 17 , contralateral 7 ± 2), but were significantly higher than the ipsilateral counts in the low-PLA₂-dose groups from experiment 1 ($P < 0.005$).

Discussion

In the rotational model used in the present study the direction of circling was ipsilateral to the hemisphere with the lower striatal dopaminergic activity (Zetterström et al. 1986; Carman et al. 1991). One day after intranigral PLA₂ and saline injections there was a spontaneous contralateral rotational asymmetry that diminished within the first postoperative week. It can be assumed that this acute and reversible effect resulted from a nonspecific dopaminergic stimulation caused by the fluid injections themselves.

Seven days postoperatively APO induced an ipsilateral asymmetry in rats treated with PLA₂. This effect was specific for PLA₂, because no asymmetry was induced by APO in the saline-treated animals. This asymmetry could still be observed 21 days after intranigral injection of higher doses of PLA₂. The comparison between low- and high-PLA₂-dose groups showed that the ipsilateral asymmetry increased with PLA₂ dose. However, it should be pointed out that the high- and low-dose groups were tested at different times after surgery, so that a comparison has to be seen with caution. Our findings are in line with the results of Cadet et al. (1989) who observed an APO-induced ipsilateral circling behavior 10, 17, and 24 days after intranigral injection of PLA₂. The results from these animal experiments indicate that intracerebral injection of PLA₂ reduced dopaminergic activity. This assumption is supported by the findings of Cadet et al. (1989) who re-

ported a reduction of the striatal concentrations of DA and its metabolites DOPAC and HVA on the side of the PLA₂ injection. An inhibitory effect of PLA₂ on dopaminergic neurotransmission has also been observed by in vitro experiments in which PLA₂ inhibited the activation of DA-sensitive adenylate cyclase in striatal tissue (Anand-Srivastava and Johnson 1981) and reduced the [³H]spiperone binding to DA receptors (Oliveira et al. 1984).

In our experiments it is unlikely that intranigral PLA₂ injections caused extensive lesions of dopaminergic SNC neurons. A selective dopaminergic SNC lesion induced by 6-OHDA causes *contralateral* rotation after APO (Carman et al. 1991), whereas in our PLA-treated animals the rotation induced by APO was ipsilateral. It should, however, be stressed that the effects of PLA₂ are probably not specific for DA neurons. In light of its profound effects on the membrane phospholipid bilayer, it is likely that PLA₂ will influence the function of virtually all membrane-bound receptors.

Taken together, our results and data from the literature suggest that PLA₂ inhibits DA activity in the brain. How could this effect be involved in the pathophysiology of schizophrenia? A reduced dopaminergic activity in the prefrontal cortex (hypofrontality) has been postulated in schizophrenia (Weinberger 1987). Recent ³¹P-NMR-spectroscopy studies showed an accelerated breakdown of membrane phospholipids in the prefrontal cortex of drug-naïve schizophrenics, which correlated with a deficit of frontal neuropsychological function (Williamson et al. 1991; Deicken et al. 1993; Pettegrew et al. 1993; Deicken et al. 1995). Further studies should clarify whether this acceleration is caused by increased PLA₂ activity in the brain of schizophrenics, as observed in their peripheral cells (Gattaz et al. 1994). In light of the present findings, it is conceivable that increased PLA₂ activity may be related to the postulated hypodopaminergic activity in the prefrontal system in schizophrenia. This conclusion is highly speculative and can only be understood as a preliminary working hypothesis for the development of new studies.

Acknowledgements This study was supported by the Deutsche Forschungsgemeinschaft, SFB 258, Project S4. We are indebted to Dr. Teschendorf and Dr. Gross (Knoll AG, Ludwigshafen) for valuable support to the experimental work

References

- Anand-Srivastava MB, Johnson RA (1981) Role of phospholipids in coupling of adenosine and dopamine receptors to striatal adenylate cyclase. *J Neurochem* 36: 1819–1828
- Bradford PG, Marinetti GV, Abood LG (1983) Stimulation of phospholipase A₂ and secretion of catecholamines from brain synaptosomes by potassium and A23187. *J Neurochem* 41: 1684–1693
- Cadet JL, Hu M, Jackson-Lewis V (1989) Behavioral and biochemical effects of intranigral injection of phospholipase-A₂. *Biol Psychiatry* 26: 106–110
- Carman LS, Gage FH, Shults CW (1991) Partial lesion of the substantia nigra: relation between extent of lesion and rotational behavior. *Brain Res* 553: 275–283

- De Groot J (1959) The rat forebrain in stereotaxic coordinates. *Verhandelingen der koninklijke Nederlandse Akademie van Wetenschappen, afd. Natuurkunde. N. V. Noord-Hollandische Uitgevers Maatschappij, Amsterdam*
- Deicken RF, Merrin E, Calabrese G, Dillon W, Weiner MW, Fein G (1993) ³¹P Phosphorous MRSI of the frontal and parietal lobes in schizophrenia. *Biol Psychiatry* 33:46A
- Deicken RF, Merrin EL, Floyd TC, Weiner MW (1995) Correlation between left frontal phospholipids and Wisconsin Card Sort Test performance in schizophrenia. *Schizophr Res* 14:177–181
- Di Chiara G, Porceddu ML, Morelli M, Mulas ML, Gessa GL (1979) Substantia nigra as an out-put station for striatal dopaminergic responses: role of a GABA-mediated inhibition of pars reticulata neurons. *Naunyn Schmiedebergs Arch Pharmacol* 306:153–159
- Farooqui AA, Hirashima Y, Horrocks LA (1992) Brain phospholipases and their role in signal transduction. In: Bazan NG, Murphy MG, Tofano G (eds) *Neurobiology of essential fatty acids*. Plenum Press, New York, pp 11–26
- Gattaz WF, Köllisch M, Thuren T, Virtanen JA, Kinnunen PKJ (1987) Increased plasma phospholipase-A2 activity in schizophrenic patients: reduction after neuroleptic therapy. *Biol Psychiatry* 22:421–426
- Gattaz WF, Hübner CK, Nevalainen TJ, Thuren T, Kinnunen PKJ (1990) Increased serum phospholipase A₂ activity in schizophrenia: a replication study. *Biol Psychiatry* 28:495–501
- Gattaz WF, Schmitt A, Maras A (1995) Increased platelet phospholipase A2 activity in schizophrenia. *Schizophr Res* 16:1–6
- Noponen M, Sanfilippo M, Samanich K, Ryer H, Ko G, Angrist B, Wolkin A, Rotrosen J (1993) Elevated PLA₂ activity in schizophrenics and other psychiatric patients. *Biol Psychiatry* 34:641–649
- Ohmichi M, Hirota K, Koike K, Kadowaki K, Miyake A, Kiyama H, Tohyama M, Tanizawa O (1989) Involvement of extracellular calcium and arachidonate in [³H] dopamine release from rat tuberoinfundibular neurons. *Neuroendocrinology* 50:481–487
- Olianas MC, De Montis GM, Concu A, Tagliamonte A, Di Chiara G (1978) Intranigral kainic acid: evidence for nigral non-dopaminergic neurons controlling posture and behavior in a manner opposite to the dopaminergic ones. *Eur J Pharmacol* 49:223–232
- Oliveira CR, Duarte EP, Carvalho AP (1984) Effects of phospholipase digestion and lysophosphatidylcholine on dopamine receptor binding. *J Neurochem* 43:455–465
- Pangerl AM, Steudle A, Jaroni HW, Rüfer R, Gattaz WF (1991) Increased platelet membrane lysophosphatidylcholine in schizophrenia. *Biol Psychiatry* 30:837–840
- Pettegrew JW, Keshavan MS, Minshew NJ (1993) ³¹P nuclear magnetic resonance spectroscopy: neurodevelopment and schizophrenia. *Schizophr Bull* 19:35–53
- Reid MS, Herrera-Marschitz M, Hökfelt T, Lindefors N, Persson H, Ungerstedt U (1990) Striatonigral GABA, dynorphin, substance P and neurokinin A modulation of nigrostriatal dopamine release: evidence for direct regulatory mechanisms. *Exp Brain Res* 82:293–303
- Rotrosen J, Wolkin A (1987) Phospholipid and prostaglandin hypotheses of schizophrenia. In: Meltzer HY (ed) *Psychopharmacology: the third generation of progress*. Raven Press, New York, pp 759–764
- Ungerstedt U, Arbuthnott GW (1970) Quantitative recording of rotational behavior in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. *Brain Res* 24:485–493
- Weinberger DR (1987) Implications of normal brain development for the pathogenesis of schizophrenia. *Arch Gen Psychiatry* 44:660–669
- Williamson P, Drost D, Stanley J, Carr T, Morrison S, Merskey H (1991) Localized phosphorous 31 magnetic resonance spectroscopy in chronic schizophrenic patients and normal controls. *Arch Gen Psychiatry* 48:578
- Zetterström T, Herrera-Marschitz M, Ungerstedt U (1986) Simultaneous measurement of dopamine release and rotational behaviour in 6-hydroxy-dopamine denervated rats using intracerebral dialysis. *Brain Res* 376:1–7